10 X Genomics Inc - Understand $TXG stock

$TXG Market Cap: $2.595 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$631.7M

TTM

Gross Margin

64.82%

TTM

Net Earnings

-$239.8M

TTM

Current Assets

$579.2M

Q2 2024

Current Liabilities

$111.0M

Q2 2024

Current Ratio

521.67%

Q2 2024

Total Assets

$929.7M

Q2 2024

Total Liabilities

$205.6M

Q2 2024

Book Value

$724.1M

Q2 2024

Cash

$379.8M

Q2 2024

P/E

-10.82

Sep 06, 2024 EST

Free Cash Flow

-$33.45M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$618.7M	$516.4M	$490.5M	$298.8M	$245.9M	$146.3M	$71.09M
YoY Change	19.81%	5.28%	64.13%	21.53%	68.06%	105.83%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$618.7M	$516.4M	$490.5M	$298.8M	$245.9M	$146.3M	$71.09M
Cost Of Revenue	$209.4M	$120.4M	$74.09M	$58.47M	$61.03M	$28.66M	$10.56M
Gross Profit	$409.3M	$396.0M	$416.4M	$240.4M	$184.9M	$117.7M	$60.53M
Gross Profit Margin	66.15%	76.69%	84.89%	80.44%	75.18%	80.41%	85.14%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$343.3M	$298.3M	$257.6M	$202.3M	$130.8M	$87.94M	$46.74M
YoY Change	15.1%	15.82%	27.3%	54.64%	48.78%	88.15%
% of Gross Profit	83.88%	75.32%	61.85%	84.17%	70.77%	74.74%	77.22%
Research & Development	$270.3M	$265.7M	$211.8M	$123.4M	$83.10M	$47.54M	$32.16M
YoY Change	1.76%	25.46%	71.63%	48.47%	74.8%	47.8%
% of Gross Profit	66.05%	67.08%	50.85%	51.33%	44.95%	40.4%	53.14%
Depreciation & Amortization	$35.51M	$25.37M	$21.12M	$14.01M	$7.066M	$3.905M	$4.305M
YoY Change	39.99%	20.13%	50.71%	98.3%	80.95%	-9.29%
% of Gross Profit	8.68%	6.41%	5.07%	5.83%	3.82%	3.32%	7.11%
Operating Expenses	$674.6M	$564.0M	$468.7M	$774.5M	$215.4M	$228.4M	$78.90M
YoY Change	19.62%	20.34%	-39.49%	259.52%	-5.68%	189.5%
Operating Profit	-$265.3M	-$167.9M	-$52.25M	-$534.1M	-$30.57M	-$110.8M	-$18.38M
YoY Change	57.99%	221.41%	-90.22%	1647.1%	-72.4%	502.8%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	$33.00K	$476.0K	$866.0K	$1.682M	$3.079M	$2.409M	$811.0K
YoY Change	-93.07%	-45.03%	-48.51%	-45.37%	27.81%	197.04%
% of Operating Profit
Other Income/Expense, Net	$16.57M	$5.973M	-$1.462M	-$334.0K	-$460.0K	-$1.634M	-$366.0K
YoY Change	177.35%	-508.55%	337.72%	-27.39%	-71.85%	346.45%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	-$248.8M	-$162.0M	-$53.72M	-$534.5M	-$31.03M	-$112.4M	-$18.74M
YoY Change	53.58%	201.54%	-89.95%	1622.28%	-72.39%	499.74%
Income Tax	$6.336M	$4.029M	$4.508M	$8.255M	$218.0K	$87.00K	$21.00K
% Of Pretax Income
Net Earnings	-$255.1M	-$166.0M	-$58.22M	-$542.7M	-$31.25M	-$112.5M	-$18.76M
YoY Change	53.67%	185.11%	-89.27%	1636.68%	-72.22%	499.54%
Net Earnings / Revenue	-41.23%	-32.15%	-11.87%	-181.61%	-12.71%	-76.88%	-26.39%
Basic Earnings Per Share	-$2.18	-$1.46	-$0.53	-$5.37	-$0.80
Diluted Earnings Per Share	-$2.18	-$1.46	-$0.53	-$5.37	-$0.80	-$1.199M	-$200.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$388.7M	$430.0M	$587.4M	$663.6M	$424.2M	$65.10M	$47.90M
YoY Change	-9.6%	-26.8%	-11.48%	56.44%	551.61%	35.91%
Cash & Equivalents	$359.3M	$219.7M	$587.4M	$663.6M	$424.2M	$65.10M	$47.90M
Short-Term Investments	$29.41M	$210.2M
Other Short-Term Assets	$18.79M	$19.21M	$14.92M	$29.60M	$8.000M	$3.000M	$2.100M
YoY Change	-2.2%	28.73%	-49.58%	270.0%	166.67%	42.86%
Inventory	$73.71M	$81.63M	$59.97M	$30.00M	$15.30M	$8.600M	$4.800M
Prepaid Expenses
Receivables	$114.8M	$104.2M	$85.25M	$51.20M	$33.40M	$28.10M	$13.30M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$1.500M	$0.00
Total Short-Term Assets	$596.0M	$635.0M	$747.6M	$774.4M	$480.8M	$106.2M	$68.10M
YoY Change	-6.14%	-15.06%	-3.46%	61.06%	352.73%	55.95%
Property, Plant & Equipment	$344.9M	$359.2M	$230.4M	$119.8M	$48.80M	$11.10M	$6.900M
YoY Change	-3.97%	55.9%	92.33%	145.49%	339.64%	60.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.062M	$7.366M	$10.92M	$12.80M	$76.30M	$6.900M	$600.0K
YoY Change	-58.43%	-32.53%	-14.71%	-83.22%	1005.8%	1050.0%
Total Long-Term Assets	$369.1M	$393.9M	$271.2M	$154.9M	$125.1M	$18.10M	$7.500M
YoY Change	-6.3%	45.24%	75.1%	23.82%	591.16%	141.33%
Total Assets	$965.1M	$1.029B	$1.019B	$929.3M	$605.9M	$124.3M	$75.60M
YoY Change
Accounts Payable	$15.74M	$21.60M	$17.35M	$4.700M	$13.00M	$8.800M	$5.400M
YoY Change	-27.14%	24.48%	269.17%	-63.85%	47.73%	62.96%
Accrued Expenses	$80.70M	$87.68M	$75.82M	$92.30M	$30.00M	$12.10M	$9.000M
YoY Change	-7.97%	15.64%	-17.85%	207.67%	147.93%	34.44%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due				$0.00	$9.900M	$4.200M	$4.200M
YoY Change				-100.0%	135.71%	0.0%
Total Short-Term Liabilities	$127.2M	$131.0M	$110.4M	$118.1M	$63.00M	$32.40M	$22.10M
YoY Change	-2.9%	18.67%	-6.56%	87.46%	94.44%	46.61%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$19.80M	$25.50M	$6.300M
YoY Change				-100.0%	-22.35%	304.76%
Other Long-Term Liabilities	$96.94M	$92.28M	$90.90M	$72.10M	$103.0M	$43.20M	$1.200M
YoY Change	5.05%	1.52%	26.08%	-30.0%	138.43%	3500.0%
Total Long-Term Liabilities	$96.94M	$92.28M	$90.90M	$72.10M	$122.8M	$68.70M	$7.500M
YoY Change	5.05%	1.52%	26.08%	-41.29%	78.75%	816.0%
Total Liabilities	$224.1M	$223.2M	$201.3M	$190.3M	$185.8M	$101.1M	$29.70M
YoY Change	0.39%	10.92%	5.76%	2.42%	83.78%	240.4%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	117.2M shares	113.9M shares	110.3M shares	101.2M shares	39.09M shares
Diluted Shares Outstanding	117.2M shares	113.9M shares	110.3M shares	101.2M shares	39.09M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $2.5954 Billion

About 10X Genomics Inc

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,259 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Industry: Laboratory Analytical Instruments Peers: Neogenomics Inc Azenta Inc Cytek Biosciences Inc Syneos Health, Inc. Maravai LifeSciences Holdings Inc Medpace Holdings Inc Pacific Biosciences of California Inc Sotera Health Co Thermo Fisher Scientific Inc